The development of a dedicated leadership team was identified as a pivotal priority in the Cancer Center strategic planning process to ensure consultative, transparent and effective decision-making. This was accomplished in the last project period through a combination of new appointments, creation of new leadership positions in the Cancer Center and reconfiguration of existing roles for optimal impact on the cancer research agenda. As part of this reorganization. Dr. Rauscher was appointed as a the sole Deputy Director of the Cancer Center with a codified succession plan should the need arise to replace the current Director, and a second Deputy Director position that was previously filled by Dr. Herlyn was eliminated. Since the introduction of these changes, the senior leadership team has worked well together, guiding an extensive and transparent consultative process that involved every administrative, scientific and educational segment ofthe Cancer Center, and leading a stepwise but decisive implementation ofthe ensuing strategic directives. Together, the senior leaders prioritized changes in the scientific alignment of Programs and Shared Resources, directed an aggressive and successful faculty recruitment effort that brought to the Cancer Center seven new faculty members appointed at all academic ranks, refocused administrative functions and decision-making processes, identified opportunities for translational and patient-oriented cancer research and developed new initiatives to expand education and mentoring, including for underrepresented minorities. Overall, the senior leadership team has catalyzed the introduction of a productive culture of collaboration and scientific exchange that has transformed the Cancer Center in the last budget period, bringing about expansive gains in NCI and cancer-related funding, and significant increase in collaborative, joint publications across the three Cancer Center Programs. This positive trajectory will continue in the next budget period, when the leadership team will guide the largest faculty and facility expansion of the Cancer Center in forty years enabled by the opening of the new Wistar Research Tower

Public Health Relevance

The newly configured Cancer Center leadership team has successfully leveraged a lean, opportunity-driven administrative infrastructure to bring about expansive gains in cancer focus, collaborative science, joint funding and innovative education to fulfill the vision of the Cancer Center of conquering cancer through outstanding research, education and partnership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8690273
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$158,283
Indirect Cost
$70,803
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Nelson, David M; Jaber-Hijazi, Farah; Cole, John J et al. (2016) Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol 17:158
Seo, Jae Ho; Rivadeneira, Dayana B; Caino, M Cecilia et al. (2016) The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biol 14:e1002507
Haut, Larissa H; Gill, Amanda L; Kurupati, Raj K et al. (2016) A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods :
Peck, Barrie; Schug, Zachary T; Zhang, Qifeng et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab 4:6
Tempera, Italo; De Leo, Alessandra; Kossenkov, Andrew V et al. (2016) Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol 90:345-55
Vazquez, Alexei; Kamphorst, Jurre J; Markert, Elke K et al. (2016) Cancer metabolism at a glance. J Cell Sci 129:3367-73
Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii et al. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol 37:208-20
Kung, Che-Pei; Murphy, Maureen E (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61-R75
Patro, Sean C; Azzoni, Livio; Joseph, Jocelin et al. (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223-31
Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72

Showing the most recent 10 out of 582 publications